Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up-Reference-Cited by-同舟云学术

Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up

Published:2024-02-28 Issue:5 Volume:38 Page:1169-1171
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Abdallah Nadine^ORCID,Witzig Thomas E.^ORCID,Kumar Shaji K.^ORCID,Lacy Martha Q.,Hayman Suzanne R.,Dispenzieri Angela^ORCID,Roy Vivek^ORCID,Gertz Morie A.^ORCID,Bergsagel P. Leif^ORCID,Rajkumar S. Vincent^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02192-z.pdf

Reference15 articles.

1. Kyle RA, Greipp PR. Smoldering Multiple Myeloma. New Engl J Med. 1980;302:1347–9.

2. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New Engl J Med. 2007;356:2582–90.

3. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I-a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993;50:95–102.

4. Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 2000;82:1254–60.

5. D’Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma. 2011;52:771–5.